

June 6, 2025

Company Name: CellSeed Inc. (TSE 7776)

Representative: Setsuko Hashimoto, Ph.D. President and CEO

Contact: Keiichiro Nakaoka Director, Corporate Management

Telephone: +81 3-6380-7490

CellSeed Enters Agreement with Tokyo Metropolitan Tama-Hokubu Medical Center for Cell Sheet Production in Esophageal Stricture Prevention

Tokyo, Japan — CellSeed Inc. is pleased to announce that it has entered into a contract with Tokyo Metropolitan Tama-Hokubu Medical Center (“Tama-Hoku MC”), a local independent administrative institution under the Tokyo Metropolitan Hospital Organization, for the production of epithelial cell sheets to be used in a self-funded regenerative treatment for esophageal stricture prevention.

Tama-Hoku MC (Location: Higashimurayama, Tokyo; Director: Dr. Kijuro Takanishi) is set to initiate the world’s first self-funded treatment for esophageal strictures using regenerative epithelial cell sheets. This innovative therapy, offered by the Department of Gastroenterological Surgery, involves transplanting cell sheets onto the wound site following endoscopic submucosal dissection (ESD) for esophageal cancer. The treatment is designed to suppress and prevent the formation of esophageal strictures, including in patients with refractory conditions post-ESD.

The medical center has submitted and received approval from the Ministry of Health, Labour and Welfare for its regenerative medicine provision plan and is currently preparing to accept patients. CellSeed has supported Tama-Hoku MC in the necessary procedures to initiate this self-funded medical treatment, including documentation related to the provision of regenerative medicine.

For inquiries regarding the treatment, please contact Tama-Hoku MC directly.

Reference

Tokyo Metropolitan Tama-Hokubu Medical Center

Website: <https://www.tmhp.jp/tamahoku/20250604.html>

Address: 1-7-1 Aobacho, Higashimurayama City, Tokyo